EcoDrugPlus

Notch Receptor 3

Ensembl ID : ENSLCRG00005006347
Gene Symbol: NOTCH3
3 Cross references
197 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSLCRG00005000662
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSLCRG00005014458
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSLCRG00005015168
Gene Symbol: NR1H4
3 Cross references
386 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSLCRG00005012202
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSLCRG00005006669
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSLCRG00005010798
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSLCRG00005002376
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSLCRG00005010814
Gene Symbol: OPRL1
3 Cross references
188 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSLCRG00005021829
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Opioid Receptor, Delta 1a

Ensembl ID : ENSLCRG00005002191
Gene Symbol: OPRD1A
3 Cross references
191 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSLCRG00005017254
Gene Symbol: OPRD1B
3 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).